KRAS and neoplasm: Analyzing codons 12, 13, and 61, they could show that tumors with wild-type KRAS were more likely to be responsive than tumors with mutant KRAS. It should be noted that the authors used irradiated tumor tissue for their analysis, although recent evidence suggests that preoperative multimodal treatment does not alter KRAS mutation status [60].